Tower Resources plc

Galliford Try Holdings PLC has landed a spot on the latest £3 billion Constructing West Midlands Framework, selected for the major works lot covering projects over £10 million. Connecting Excellence Group Plc has completed its first acquisition, buying James Gray Recruitment, and has grown its Bitcoin holding to over 81 coins, worth around £5.25 million. Bradda Head Lithium Ltd has intersected visible spodumene mineralisation in all three of its first Whistlejacket holes in Arizona, with lab assays now the next key test. Tower Resources PLC has secured a one-year extension to its exploration licence at Thali in Cameroon and is now working towards a drilling campaign targeted for Q2 2027. Premier African Minerals Ltd has raised around £1.2 million to restart operations at its Zulu Lithium project in Zimbabwe, with the plan now focused on processing ore already sitting on the stockpile.

Tower Resources has raised £400,000 to bolster working capital while it waits on government approvals in Namibia and Cameroon, with both farm-out deals potentially completing as early as July. Buccaneer Energy reported an 18% rise in proved reserves in an independent review tied to its bank credit facility, with the borrowing base confirmed at $4.45 million and more growth expected as production ramps up. Light Science Technologies secured up to £1.66 million in orders for its passive fire protection division since April's RLUK Injection acquisition, becoming a vertically integrated business spanning installation and material supply. Eco Buildings Group has started building a second-generation AI-enabled manufacturing line in Albania, the first major use of its recent £2.35 million fundraise, with the new line expected to be operational by the fourth quarter. Fieldwork Robotics, backed by Frontier IP Group, picked up a £300,000 investment from SEED Innovations to roll out its soft fruit harvesting robots, with multi-robot fleets potentially on farms from 2027 if trials succeed. ImmuPharma flagged new research suggesting its lead drug candidate could help treat glioblastoma, an aggressive brain cancer, while its main focus remains autoimmune disease.